Argenx
ARGX
#493
Rank
NZ$85.47 B
Marketcap
NZ$1,368
Share price
-0.06%
Change (1 day)
44.74%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2026 (TTM): NZ$2.57 Billion

According to Argenx 's latest financial reports the company's current earnings are NZ$4.66 Billion. In 2025 the company made an earning of NZ$2.15 Billion, an increase over its 2024 earnings that were of NZ$0.14 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$2.57 B19.64%
2025 NZ$2.15 B1400.64%
2024 NZ$0.14 B-127.97%
2023 -NZ$0.52 Billion-58.25%
2022 -NZ$1.23 Billion80.17%
2021 -NZ$0.69 Billion
2019 -NZ$0.34 Billion124.86%
2018 -NZ$0.15 Billion131.81%
2017 -NZ$64.19 Million
2015 -NZ$30.99 Million
2013 -NZ$18.75 Million